Vitestro Gains CE Marking for Autonomous Blood Drawing Device

Vitestro, a pioneer in medical robotics, has received a CE marking for its innovative automated blood-drawing device. This marks a significant milestone for the company, acknowledging that the device meets the requirements of the European Medical Device Regulation (MDR) and is now approved for commercial use across the European Union. 
 
Vitestro is the first company ever to achieve CE marking for an autonomous blood drawing device.
 
Co-founder and CEO, Toon Overbeeke, commented, “While this CE marking represents a major step forward for Vitestro, it also marks a transformational moment for healthcare at large. This innovation introduces a completely novel type of medical device—one that allows European hospitals to use autonomous technology to perform invasive medical procedures independently. We believe this technology is foundational, setting a new global standard that will benefit patients and help hospitals prepare for a challenging future.”
 
Through a combination of advanced imaging technology and robotics, the device enables hospitals and labs to provide accurate autonomous blood draws, reducing the need for manual handling and improving patient and clinician satisfaction. Vitestro has managed to automate the missing step in total lab automation. This is critical as clinical laboratories are experiencing a severe staffing shortage.
 
Maxine Moor, VP of Commercial Europe, said, “Vitestro has been interacting with clinical labs throughout Europe for the past years. They confirmed the huge need for phlebotomy automation and couldn’t wait for this innovation! We are eager to start the implementation of our devices in hospitals and laboratories in the coming 12 months. While we will start within the Netherlands and Denmark, we have huge, broader international ambitions. With the CE mark, we are also meeting regulatory demands for the UK market.”